Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Carboplatin,CRBP001,2021,USA,MDV,350,68,62,38,27.5,32,85,12,15,35,25,25,45,30,15,10,20,40,30,18,7,4,9,5,28,65,42,Paclitaxel/Carboplatin,Docetaxel/Carboplatin,Carboplatin/Pemetrexed,Carboplatin/Gemcitabine,5,3,2,22,75,55,15,45,40,60,2
Carboplatin,CRBP002,2022,Canada,Claim Database,420,72,58,42,28.1,35,80,15,12,38,22,28,40,35,18,7,18,38,32,20,8,5,10,6,30,62,45,Docetaxel/Carboplatin,Gemcitabine/Carboplatin,Carboplatin/Paclitaxel,Carboplatin/Vinorelbine,4,2,4,25,78,58,12,48,40,65,3
Carboplatin,CRBP003,2023,UK,MDV,280,65,65,35,26.8,28,90,10,18,32,28,22,50,25,17,8,22,42,26,15,6,3,8,4,25,70,40,Carboplatin/Gemcitabine,Paclitaxel/Carboplatin,Carboplatin/Docetaxel,Carboplatin/Vinorelbine,6,1,3,20,72,52,18,42,40,55,2.5
